Paclitaxel bound to albumin so it needs no solvent and no steroid premedication. Adding it to gemcitabine and cisplatin looked promising in a small study of bile duct and gallbladder cancer but did not lengthen life in the 452-patient SWOG S1815 trial.
Nab-paclitaxel is a solvent-free, albumin-bound formulation of paclitaxel that stabilises microtubules and arrests mitosis; the albumin carrier uses gp60 and SPARC-mediated transport and allows higher doses without the hypersensitivity of Cremophor. It is approved for metastatic breast cancer (United States 2005, European Union 2008), non-small-cell lung cancer (2012) and, with gemcitabine, metastatic pancreatic adenocarcinoma (MPACT, 2013). In biliary tract cancer, a 60-patient MD Anderson and Mayo phase 2 of gemcitabine, cisplatin and nab-paclitaxel (22 percent gallbladder cancer) reported a partial response rate of 45 percent, median progression-free survival of 11.8 months and median overall survival of 19.2 months, which set up SWOG S1815. That randomised phase 3 (441 analysable patients, 16 percent gallbladder cancer) found no overall survival difference between the triplet and gemcitabine plus cisplatin (14.0 versus 13.6 months, hazard ratio 0.91, p 0.41) or progression-free survival (7.5 versus 6.3 months, hazard ratio 0.89); exploratory analyses suggested greater progression-free survival benefit in gallbladder cancer (interaction p 0.01) and in locally advanced disease, but not in overall survival. It therefore has no place in routine biliary treatment and is not licensed or commissioned for it in the UK; several Chinese phase 2 trials continue to test gemcitabine plus nab-paclitaxel backbones with PD-1 antibodies in gallbladder cancer.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Microtubule stabiliser delivered as 130 nm albumin nanoparticles.
1.Nab-paclitaxel slips into a pocket on its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
| Region | Year | Indication |
|---|---|---|
| US | 2005 | Metastatic breast cancer after combination chemotherapy · FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24d10449-2936-4cd3-b7db-a7683db721e4 |
| EU | 2008 | Metastatic breast cancer; later pancreatic (2013) and non-small-cell lung cancer (2015) · EMA EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/abraxane |
| US | 2013 | First-line metastatic pancreatic adenocarcinoma with gemcitabine (MPACT) · FDA label (DailyMed) |
| UK | 2017 | Untreated metastatic adenocarcinoma of the pancreas with gemcitabine; NICE TA476 (6 September 2017, replacing TA360) recommends it only if other combination chemotherapies are unsuitable and the person would otherwise have gemcitabine alone, with the patient access scheme discount · https://www.nice.org.uk/guidance/ta476 |
Read for the class this product belongs to (taxanes) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Nab-paclitaxel" OR ABSTRACT:"Nab-paclitaxel" OR TITLE:"Abraxane" OR ABSTRACT:"Abraxane" OR TITLE:"ABI-007" OR ABSTRACT:"ABI-007") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Nab-paclitaxel, not a curated reading list.
Shares Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes, Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer, Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer, Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer.
Shares Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes, Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer, Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer, Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer.
Shares NEONAX, NEOLAP, PRIMUS 001, STARPAC2.
Shares Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes, Albumin-bound Paclitaxel (II) in Combination With Gemcitabine as First Line Therapy for Metastatic Pancreatic Cancer, Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer, ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Shares A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC, Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer, QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride, The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breas.
Shares Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis, QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer, Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer, Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer.
Shares Gemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer, An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies, Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer, Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer.
Shares Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer, A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer, Irinotecan Liposome,Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer, PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients.